Zou Chen, Guo Wentao, Mu Wenbo, Wahafu Tuerhongjiang, Li Yicheng, Hua Long, Xu Boyong, Cao Li
Department of Orthopaedics, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Bone Joint Res. 2024 Oct 2;13(10):535-545. doi: 10.1302/2046-3758.1310.BJR-2024-0024.R2.
We aimed to determine the concentrations of synovial vancomycin and meropenem in patients treated by single-stage revision combined with intra-articular infusion following periprosthetic joint infection (PJI), thereby validating this drug delivery approach.
We included 14 patients with PJI as noted in their medical records between November 2021 and August 2022, comprising eight hip and seven knee joint infections, with one patient experiencing bilateral knee infections. The patients underwent single-stage revision surgery, followed by intra-articular infusion of vancomycin and meropenem (50,000 µg/ml). Synovial fluid samples were collected to assess antibiotic concentrations using high-performance liquid chromatography.
The peak concentrations of vancomycin and meropenem in the joint cavity were observed at one hour post-injection, with mean values of 14,933.9 µg/ml (SD 10,176.3) and 5,819.1 µg/ml (SD 6,029.8), respectively. The trough concentrations at 24 hours were 5,495.0 µg/ml (SD 2,360.5) for vancomycin and 186.4 µg/ml (SD 254.3) for meropenem. The half-life of vancomycin was 6 hours, while that of meropenem ranged between 2 and 3.5 hours. No significant adverse events related to the antibiotic administration were observed.
This method can achieve sustained high antibiotic concentrations within the joint space, exceeding the reported minimum biofilm eradication concentration. Our study highlights the remarkable effectiveness of intra-articular antibiotic infusion in delivering high intra-articular concentrations of antibiotics. The method provided sustained high antibiotic concentrations within the joint cavity, and no severe side-effects were observed. These findings offer evidence to improve clinical treatment strategies. However, further validation is required through studies with larger sample sizes and higher levels of evidence.
我们旨在确定接受人工关节周围感染(PJI)后单阶段翻修联合关节内输注治疗的患者关节液中万古霉素和美罗培南的浓度,从而验证这种给药方法。
我们纳入了2021年11月至2022年8月病历中记录的14例PJI患者,包括8例髋关节感染和7例膝关节感染,其中1例患者双侧膝关节感染。患者接受单阶段翻修手术,随后关节内输注万古霉素和美罗培南(50,000μg/ml)。收集关节液样本,采用高效液相色谱法评估抗生素浓度。
注射后1小时观察到关节腔内万古霉素和美罗培南的峰值浓度,平均值分别为14,933.9μg/ml(标准差10,176.3)和5,819.1μg/ml(标准差6,029.8)。24小时的谷浓度,万古霉素为5,495.0μg/ml(标准差2,360.5),美罗培南为186.4μg/ml(标准差254.3)。万古霉素的半衰期为6小时,而美罗培南的半衰期在2至3.5小时之间。未观察到与抗生素给药相关的显著不良事件。
该方法可在关节腔内实现持续高抗生素浓度,超过报道的最低生物膜根除浓度。我们的研究突出了关节内抗生素输注在提供高关节内抗生素浓度方面的显著有效性。该方法在关节腔内提供了持续高抗生素浓度,且未观察到严重副作用。这些发现为改进临床治疗策略提供了证据。然而,需要通过更大样本量和更高证据水平的研究进行进一步验证。